Cargando…

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential

Detalles Bibliográficos
Autores principales:	Peakman, Mark, von Herrath, Matthias
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Perspectives in Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927927/ https://www.ncbi.nlm.nih.gov/pubmed/20805382 http://dx.doi.org/10.2337/db10-0630

Ejemplares similares

Viral Trigger for Type 1 Diabetes: Pros and Cons
por: Filippi, Christophe M., et al.
Publicado: (2008)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited
por: Atkinson, Mark A., et al.
Publicado: (2011)

Antigen-Based Therapy for the Treatment of Type 1 Diabetes
por: Tian, Jide, et al.
Publicado: (2009)

Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
por: Staeva, Teodora P., et al.
Publicado: (2013)

How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?
por: Haller, Michael J., et al.
Publicado: (2021)

Immunomodulation by Mesenchymal Stem Cells : A Potential Therapeutic Strategy for Type 1 Diabetes
por: Abdi, Reza, et al.
Publicado: (2008)

The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes
por: Wahren, John, et al.
Publicado: (2012)

The Streetlight Effect in Type 1 Diabetes
por: Battaglia, Manuela, et al.
Publicado: (2015)

The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes
por: Coppieters, Ken, et al.
Publicado: (2018)

Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes
por: Petrelli, Alessandra, et al.
Publicado: (2021)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

Central Role for Interleukin-2 in Type 1 Diabetes
por: Hulme, Maigan A., et al.
Publicado: (2012)

Hypoglycemia in Type 1 Diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2010)

Genetics of Type 1 Diabetes: What's Next?
por: Pociot, Flemming, et al.
Publicado: (2010)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

Non-antigenic and antigenic interventions in type 1 diabetes
por: Rydén, Anna KE, et al.
Publicado: (2013)

Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Optimizing the path from bench to bedside
por: Bresson, Damien, et al.
Publicado: (2009)

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021)

Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
por: Pham, Minh N., et al.
Publicado: (2016)

Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes
por: Sellmeyer, Deborah E., et al.
Publicado: (2016)

Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease
por: Ziegler, Anette-G., et al.
Publicado: (2016)

The “Perfect Storm” for Type 1 Diabetes: The Complex Interplay Between Intestinal Microbiota, Gut Permeability, and Mucosal Immunity
por: Vaarala, Outi, et al.
Publicado: (2008)

The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
por: Purcell, Anthony W., et al.
Publicado: (2019)

Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?
por: O’Kell, Allison L., et al.
Publicado: (2017)

β-Cell Mass and Type 1 Diabetes: Going, Going, Gone?
por: Akirav, Eitan, et al.
Publicado: (2008)

It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes
por: Creusot, Rémi J., et al.
Publicado: (2014)

A Global Overview of Precision Medicine in Type 2 Diabetes
por: Fitipaldi, Hugo, et al.
Publicado: (2018)

Metabolic syndrome – Removing roadblocks to therapy: Antigenic immunotherapies()
por: Coppieters, Ken T., et al.
Publicado: (2014)

Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure?
por: Dunne, Jessica L., et al.
Publicado: (2012)

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes
por: Eizirik, Decio L., et al.
Publicado: (2021)

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Learning From Molecular Genetics: Novel Insights Arising From the Definition of Genes for Monogenic and Type 2 Diabetes
por: McCarthy, Mark I., et al.
Publicado: (2008)

Air Pollution and Type 2 Diabetes: Mechanistic Insights
por: Rajagopalan, Sanjay, et al.
Publicado: (2012)

Peptide Immunotherapy for Type 1 Diabetes—Clinical Advances
por: Smith, Emma L., et al.
Publicado: (2018)

Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
por: Palmer, Allyson K., et al.
Publicado: (2015)

The Role of TCF7L2 in Type 2 Diabetes
por: del Bosque-Plata, Laura, et al.
Publicado: (2021)

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
por: Davidson, Jaime A, et al.
Publicado: (2014)

Islets in Type 2 Diabetes: In Honor of Dr. Robert C. Turner
por: Bonner-Weir, Susan, et al.
Publicado: (2008)

Potential viral pathogenic mechanism in human type 1 diabetes
por: Schneider, Darius A., et al.
Publicado: (2014)

Epigenetics: A Molecular Link Between Environmental Factors and Type 2 Diabetes
por: Ling, Charlotte, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3gp5a18pkl3tugcrpm2p1i6apu